A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Clinical Trial

Official title: A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-cell Non-Hodgkin Lymphoma (NHL)

Status Not yet recruiting

Clinical Trial Summary

This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).

Clinical Trial Description

The study will include the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), Treatment and Follow-up. ;

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Non-Hodgkin
• Refractory or Relapsed B-cell Non-Hodgkin Lymphoma

• NCT number: NCT03299738
• Study type: Interventional
• Source: Cellular Biomedicine Group Ltd.
• Contact: Huilai Zhang
• Phone: +86-022-23340123
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: December 2017
• Completion date: August 2019